*April 2021*

The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy. Read more.

Donate

Support EGFR

Latest Newsletter

Get Social: Twitter

Categories